Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776732 | 0.83 | HRH3 (0.47) | HRH3KDM4EPOLBALDH1A1KDM2B | |
| SCHEMBL4021961 | 0.82 | KDM4E (0.49) | HRH3KDM4EPOLBALDH1A1KDM2B | |
| Benzaldehyde SCHEMBL4772493 | 0.74 | KDM4E (0.42) | HRH3KDM4EPOLBALDH1A1KDM2B | |
| SCHEMBL4019459 | 0.73 | RORC (0.57) | KDM4EALDH1A1LMNA | |
| SCHEMBL4019955 | 0.73 | RORC (0.57) | KDM4EALDH1A1LMNA | |
| SCHEMBL4019872 | 0.72 | KMT2A (0.37) | ALDH1A1KDM2BLMNA | |
| SCHEMBL4025447 | 0.70 | RORC (0.40) | POLBALDH1A1KDM2BLMNA | |
| SCHEMBL9920449 | 0.70 | MCL1 (0.58) | ALDH1A1MCL1 | |
| SCHEMBL4780139 | 0.69 | HRH3 (0.42) | HRH3ALDH1A1LMNA | |
| SCHEMBL4021517 | 0.69 | HRH3 (0.42) | HRH3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | HRH3 1935/4885KDM4E 4110/4885POLB 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.